Disease · EFO_0004599
acute graft vs. host disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. acute graft vs. host disease. Diseases, record EFO_0004599. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004599
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- acute graft vs. host disease
- Open Targets ID
- EFO_0004599
- Highest stage of its drugs
- Phase 3, for 3 of its 22 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DECITABINE | CHEMBL1201129 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AUTOLOGOUS CORD BLOOD | CHEMBL4594461 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| SIZAVALEUCEL | CHEMBL5095445 | Cell | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELTROMBOPAG | CHEMBL461101 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IMLIFIDASE | CHEMBL4297981 | Enzyme | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISATUXIMAB | CHEMBL3545131 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISCALIMAB | CHEMBL4298210 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLENDALIZUMAB | CHEMBL3990025 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Phase 2 | https://conductscience.org/library/genes/727 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Phase 2 | https://conductscience.org/library/genes/952 | Drugs and targets |
| CD40 | Tumor necrosis factor receptor superfamily member 5 | 1 | Tumor necrosis factor receptor superfamily member 5 inhibitor | Phase 2 | https://conductscience.org/library/genes/958 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 1 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 3 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| MPL | Thrombopoietin receptor | 1 | Thrombopoietin receptor agonist | Phase 2 | https://conductscience.org/library/genes/4352 | Drugs and targets |
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03781414 | Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension | Phase 2 | 129 | 2024-07-03 | Liver Transplant Rejection | ISATUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03897205 | An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients | Phase 2 | 30 | 2024-02-28 | Kidney Transplant Rejection | IMLIFIDASE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02245412 | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease | Phase 2 | 25 | 2017-10-06 | Acute Graft-Versus-Host Disease, GIGVHD | OLENDALIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03718533 | Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function | Phase 2 | 10 | 2024-02-05 | Poor Graft Function | ELTROMBOPAG | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03721965 | Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects | Phase 1/2 | 2 | 2023-02-21 | Acute Graft-versus-host Disease | ITACITINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03663335 | Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients | Phase 2 | 418 | Kidney Transplantation | ISCALIMAB, MYCOPHENOLATE MOFETIL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05669079 | Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT | Phase 3 | 100 | Poor Graft Function | DECITABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05907499 | Decitabine for Poor Graft Function Post Allo-HSCT | Phase 3 | 76 | Poor Graft Function | DECITABINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03363945 | Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants | Phase 3 | 30 | Kidney Transplant Rejection | SIZAVALEUCEL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03437603 | Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | 20 | Poor Graft Function | ELTROMBOPAG | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Imlifidase vs Plasma Exchange: Number of Patients With Graft Loss Within 180 Days of Treatment | 5 of 19 | 0 of 10 | 29 | NCT03897205 | Trial comparisons |
| Imlifidase vs Plasma Exchange: deaths from any cause | 1 of 19 | 0 of 10 | 29 | NCT03897205 | Trial comparisons |
| Imlifidase vs Plasma Exchange: serious adverse events | 3 of 19 | 3 of 10 | 29 | NCT03897205 | Trial comparisons |
| Eltrombopag (On-treatment) vs Eltrombopag (Post-treatment Survival Follow-up): deaths from any cause | 0 of 10 | 2 of 7 | 17 | NCT03718533 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0004599
GET https://conductscience.org/api/diseases/v1/EFO_0004599/drugs?page=2